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Abstract: Curcumin is a natural product with several thousand years of heritage. Its traditional 
Asian application to human ailments has been subjected in recent decades to worldwide 
pharmacological, biochemical and clinical investigations. Curcumin’s Achilles heel lies in 
its poor aqueous solubility and rapid degradation at pH ~ 7.4. Researchers have sought to 
unlock curcumin’s assets by chemical manipulation. One class of molecules under scrutiny 
are the monocarbonyl analogs of curcumin (MACs). A thousand plus such agents have 
been created and tested primarily against cancer and inflammation. The outcome is clear.  
In vitro, MACs furnish a 10–20 fold potency gain vs. curcumin for numerous cancer cell 
lines and cellular proteins. Similarly, MACs have successfully demonstrated better 
pharmacokinetic (PK) profiles in mice and greater tumor regression in cancer xenografts  
in vivo than curcumin. The compounds reveal limited toxicity as measured by murine 
weight gain and histopathological assessment. To our knowledge, MAC members have not 
yet been monitored in larger animals or humans. However, Phase 1 clinical trials are 
certainly on the horizon. The present review focuses on the large and evolving body of 
work in cancer and inflammation, but also covers MAC structural diversity and early 
discovery for treatment of bacteria, tuberculosis, Alzheimer’s disease and malaria. 
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1. Introduction 
Curcumin (1, diferuloylmethane, Figure 1) is an ancient and tantalizing molecule characterized by 
nicknames such as Indian Saffron, The Spice of Life and Indian Solid Gold. Extracted from fresh dried 
roots of Curcuma Longa and related species in the ginger family, it is distributed annually in over 
million ton quantities world-wide as the rough and heterogeneous extract “turmeric”, which contains over 
two hundred other natural small molecules. The mixture with 2%–8% curcumin can be refined to deliver 
both pure 1 and isomeric mixtures of the agent dominated almost entirely by the enol isomers (Figure 1). 
Many varieties of the natural product are popular primarily as food coloring and flavoring agents, 
spices, cosmetics, botanical supplements and medicines [1]. The internet is rich with the range of 
products available. 
 
Figure 1. Curcumin and its demethoxy isomers isolated from turmeric. 
The medical history of turmeric and curcumin, particularly in Asia, is extensive and stretching from 
centuries-old traditional ayurvedic practice to modern times. In the current environment that combines 
medicinal chemistry, pharmacology, biochemistry and molecular biology, cucumin has surfaced as  
a pleiotropic agent able to interact directly or indirectly with a multitude of cellular proteins while 
appearing to exert a whole organism effect on an extensive range of human disorders. The literature 
includes claims that the molecule can serve as an antioxidant, antimicrobial, antifungal, antiinflammatory 
and wide-ranging anticancer agent. In the latter category, it has been reported to elicit benefits in 
connection with drug-resistance and metastasis. The extended list includes protection for heart ailments, 
arthritis, wound healing, depression and Alzheimer’s disease among many others. It is not surprising, 
then, that considerable health care research has been devoted to testing the efficacy of curcumin as  
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time frame, the NIH reported over 90 clinical trials with curcumin integral to the therapy under 
investigation [2]. Yet no single curcumin-containing agent has been approved by the FDA. One possible 
reason could be the limited opportunity for protection of such a compound in an aggressive marketplace 
and a historical geographical context. In 1995, two researchers at the University of Mississippi (UM) 
sought and won a patent for curcumin’s ability to heal wounds. They also garnered the exclusive  
right to market turmeric. Within two years the Indian government’s Council of Scientific and 
Industrial Research protested the patent as biopiracy and challenged its novelty by showing that 
wound-healing is an ancient practice supported by equally ancient Sanskrit documents. Needless to 
say, the patent was revoked and India’s “national molecule” was rescued from exploitation by UM and 
its faculty [3]. 
In parallel with recent research on parent curcumin, many laboratories around the globe went in 
search of easily prepared novel agents with biological properties similar or superior to those of curcumin. 
A major chemical class, the monocarbonyl analogs of curcumin (MACs) evolved and is the focus of 
this review. 
 
Figure 2. Curcumin mimics. FLLL series (4), GO-series (GO-Y030), MACs as acycle or 
ring (5), EF24 (6), EF31 (R = H, 7a), UBS109 (R = Me, 7b). 
One might conclude that the driving force for this curcumin re-direction arose from the patent conflict 
between UM and India. However, a number of other crucial factors have been at work. That most often 
quoted is the meager bioavailability of the drug in humans resulting from aqueous insolubility,  
low absorption, rapid metabolism, poor chemical stability and fast systemic elimination [4] These 
considerations noted in the overwhelming majority of MAC papers cited herein imply the molecule to 
be less tantalizing as a drug candidate than its ancient legacy might otherwise suggest. Influential 
structural modifications of curcumin that improve stability and solubility involve elimination of the 
hydrolysis-prone keto-enol functionality in 1–3 [5–8] and incorporate a range of alternative substituents 
on the terminal phenyl rings. Two such replacements involve dialkyl substitution of the hydrogens on 
the carbon between the two carbonyl groups in the diketo tautomer (the FLLL family, 4, Figure 2) [9] or 
installation of a single carbonyl group either as an acyclic agent or embedded in a small ring (the MAC 
family) (5, Figure 2). Both avoid the extraordinarily rapid decomposition of curcumin at pH 6.5 and 
above in aqueous medium [10] and deliver improved pharmacokinetic profiles in mouse models [11–14]. 
Enhancement of solubility is likewise readily achieved by appropriate substituent modification of 
MAC structures, the acyclic GO-series represented by GO-Y030 (Figure 2) [15–17] and combination 
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of pyridines and piperidines such as EF24 (6) [18] and UBS109 (7b) [19] providing excellent 
examples. Accordingly, such molecular structures have attracted interest as models for development of 
novel curcumin mimics. On the other hand, not all of the natural product’s liabilities are bypassed by 
structural modification. MACs such as 6 and 7b like curcumin [4,20,21], experience rapid reductive 
metabolism and generate metabolites that carry only a fraction of the activity of the fully unsaturated 
parent compounds [19]. 
Other reasons for turning from 1 to MACs are ease of synthesis [22,23] selectivity [9,24,25] and 
recognition that the pleiotropic nature [26] of the curcumin-like architecture permits rapid evaluation 
of drug potential for currently troublesome disorders such as highly resistant bacteria, Alzheimer’s 
syndrome, HIV, tuberculosis, malaria and diabetes [22,27]. Several excellent reviews detailing the 
diversity, applications and biological foundations of MACs for utility in human disease have appeared 
in the recent past [10,22,27–32]. 
2. Structural Diversity 
2.1. 2D Diversity 
A casual survey of both reviews of the monocarbonyl curcumin literature and the vast collection of 
supporting peer-reviewed research papers reveals hundreds of variations on the theme created by 
elimination or restructuring of the keto-enol moiety in curcumin. Nonetheless, almost all of the individual 
compounds can be clustered into two core templates in the diarylpentanoid class of molecules, namely 
the acyclic form 8 and the cyclic variation 9 (Figure 3). 
 
Figure 3. Core structures representing the diversity of individual MAC derivatives. 
The majority of analogs are symmetrical consistent with ease of synthesis, however, many asymmetric 
versions have been prepared including chalcone variants [28,33]. The terminal aromatic rings may contain 
up to three different substituents and one or more nitrogen atoms in the ring to deliver heteroaromatic 
pyridine analogs (8, 9, Y = Z = N) with N located at o, m and p sites. The most popular phenyl ring 
substituents are OR and OH followed by halogen atoms. However, N- and C-linked substituents have 
been probed as well. The terminal phenyls have also been replaced with heteroaromatic rings such as 
thiophene in a few cases. The central ring in 9 most often appears as a 5- or 6-membered ring, 
although a number of 7-membered ring congeners are known. The central 6-ring is often accompanied 
by X = C, NR, O, S and SO2. Surprisingly, no B-R or Se derivatives have appeared to date. Finally, the 
central carbonyl group is the overwhelming favorite functionality at its position, although C=NOH, 
C=C(CN)2 and related substances have been prepared. A sampling of individual structures representing 
MAC diversity is presented along with their biology below. 
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2.2. 3D Diversity 
Apart from the topological and structural variations described above, each of the mono-carbonyl 
analogs adopts a unique 3D structure in the solid state and a corresponding conformational profile in 
solution. The implication is that the delicate requirements for a molecule to bind and influence the 
behavior of a target protein will be dependent on the 3D geometry of the ligand. Thus, 2D 
representations such as 10–16 imply an undeserved similarity in terms of their complementarity to a 
chiral protein pocket. This is illustrated with the X-ray crystal structures of a small subset of MACs, 
several of which are substituted with fluorine as a rather diminutive replacement for hydrogen (Figure 4). 
 
 
Figure 4. Five X-ray crystal structure geometries of selected diarylpentanoid MACs. In the 
structures shown, the aromatic rings are each substituted with fluorine at the ortho-postions 
C2 and C6 or without substituents; (a) Acyclic series exhibiting planar geometry;  
(b) Central 6-membered ring with an approximate plane of symmetry bisecting an 
envelope conformation; (c) Central 5-membered ring with a twist ring conformation;  
(d) 7-membered ring derivatives presenting two different conformations of the central ring. 
The structures depicted in Figure 4 reveal four separate 3D motifs. Acyclic fluorinated 10 [34] and 
the unfluorinated analog 13 [35–37] are both fully planar. Nonetheless, a polymorphic form of 13 [38] 
and a number of substituted analogs [38–41] adopt a twisted shape. Many MAC entries in the 
Cambridge Structural Database (CSD) show distortions from planarity, but the great majority involve 
metal complexation to one or both of the C=C double bonds. In the uncomplexed acyclic cases,  
ortho-fluoro substitution of the terminal phenyl rings does not perturb planarity. However, larger 
a b c 
10 11 12 
13 14 15 
Y(X) = CH(CH2), 2-CF(CH2), 2,5-CF(CH2), 2,6-CF(CH2), 
2-CF,5-COMe(CH2), 2-CF(NH2+), 2-CF(NHMe+) 
R = H, Me 
d
16a 16b
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ortho-groups, e.g., CF3 or i-Pr, accompanied by steric hindrance will certainly induce non-planarity. 
Introduction of a 6-membered central ring, on the other hand, produces a butterfly shape as in 14 
regardless of the nature of X (C, N, O or S) [42–51]. Interestingly, a variety of structural modifications 
including the formation of a nitrogen heterocycle, neutral or charged (Figure 4b, variations of X and Y), 
results in a very similar conformation verified by molecular superposition of the structures. One 
apparent exception to this observation is the cationic N-dimethyl analog 14 (X = NMe2+, terminal 
phenyl rings carry p-NMe2) [52]. The six-membered ring is a distorted half-chair, while the distal 
phenyl rings are twisted away from the butterfly shape. The 5-membered variant 12 (Figure 4c) adopts 
a highly unsymmetrical structure resulting from the adoption of a twist conformation by the central 
ring [42]. The X-ray structures of a family of nearly 20 analogs of the corresponding unfluorinated 
analog 15 (R = H) lacking ortho-substituents on the phenyl rings are fully planar similar to 10 and  
13 [53]. Thus, it appears that internal steric effects occasioned by the four o-fluorine atoms in 12 is the 
basis for the observed asymmetric non-planarity. Other more bulky ortho-substituents can be expected 
to enhance the effect. A complement is the structure of 15 (R = Me) [54]. This molecule likewise 
exhibits a twisted 5-membered ring conveying both modest non-planarity and asymmetry to the overall 
molecular shape. Within the same MAC family, 15 (R = H) has recently been isolated as two different 
but nearly superimposable conformations representing a second polymorph of the compound. The 
origin of the two conformers and the new polymorph has been ascribed to C-H---O, π-π and C-H---π 
interactions [55]. Two 7-membered ring analogs (16a,b, Y = CH, X = CH2-CH2, Figure 4d) reveal yet 
other geometrical options in the form of two different conformers for the central ring and novel 
positioning of the terminal phenyl groups [56]. 
The message of this analysis is that 2D representations of MACs decorated with a range of substituents 
provide an incomplete picture of the fundamental nature of the interactions between potential drugs 
and their protein targets. Furthermore, the X-ray structures discussed above still reveal only the “tip of 
the iceberg”. The molecular shapes captured by small molecule crystal structures do not necessarily 
represent those for the same molecule bound to a protein. In solution, ligand molecules are properly 
described by an ensemble of conformations, one of which is likely to match the conformer within  
a protein pocket. It has been shown that low population conformers (<20%) are often the favored 
structure [57–59]. In the MAC context, head-to-head comparisons of the bio-potencies of 5- and  
6-membered ring analogs occasionally reveal sharp differences most likely due to a combination of 
substituent effects, overall molecular shape and the conformation that is selected for binding to 
specific targets (Figure 3). Unfortunately, this makes SAR development complicated and reasoned 
molecular design difficult. 
One recent study concerned with the interaction of pleiotropic MACs with kinases has nonetheless 
attempted to illustrate that the binding of similar core structures is tempered by both molecular shape 
and specific substitution pattern [26]. EF31 (7a and 14, Y = N, X = NH) was used to screen a  
50-member kinase library, and the top 12 enzymes were then subjected to IC50 inhibition 
measurements with five MACs. AKT1 and AKT2 delivered the lowest range of values (IC50 0.02 to 
>100 μM) followed by a kinetic analysis to strongly suggest that the dominant mechanism for 
inhibition is competitive displacement of ATP. Accordingly, a structure-based analysis performed with 
AKT2. The top hit, N-protonated EF31 (IC50 0.02 μM) was subsequently docked into the ATP binding 
and shown to make hydrogen bonds from its carbonyl group (CO---HN(CH2)) and one of the pyridine 
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nitrogens, a salt bridge to Glu236 (N-H---OC(O)) and several attractive hydrophobic contacts. 
Comparison with protonated EF24 (7a and 14, Y = C-F, X = NH2) with 40-fold lower potency (IC50 
0.8 μM) demonstrated loss of a key hydrogen bond and introduction of weaker ligand-protein 
associations. Protonated UBS109 (7b and 14, Y = N, X = NMe), lowering potency still further (IC50 
1.9 μM), was predicted to relocate somewhat in the binding site to accommodate the slightly bulky 
equatorial N-methyl group. This movement not only created a pair of close steric contacts, but also 
eliminated the electrostatically enhanced C=O-HN(Lys181) hydrogen bond. The largest structure 
activity perturbation takes place with 7b/14 (X = S, Y = N; IC50 > 100 μM) relative to EF31 (7a) in 
which the central NH is replaced by sulfur, and the AKT2 potency drops by several thousand fold. 
Molecular modeling suggests a major relocation of the molecule in the binding pocket and the loss of 
two key electrostatically enhanced H-bonds (i.e., from C=O and N-H). The relatively large sulfur atom 
and the expanded volume of the molecule due to its long S-C bonds are contributing factors. The 
reader is referred to the original literature [26] for additional details. One concludes that relatively 
small changes in drug-ligand structure, not necessarily apparent from comparison of flat textual 
structures (e.g., Figure 4), can have a drastic effect on the degree of binding with target proteins when 
they are known. In such circumstances, structure-based models can prove useful for understanding 
quantitative structure activity relationships (QSARs) and generating ideas for further synthesis and 
bioassay. In such cases, a ligand-based analysis can sometimes compensate for the lack of detailed 
structure. Unfortunately, in the sequel, most of the cases discussed do not yet allow a consideration of 
specific ligand-protein interactions. However, recognition that structural variation as illustrated in 
Figure 4 and the accompanying discussion, is operating beneath the cover of superficial structural 
comparison can alert one to expect both unintended frustration and surprises. 
In this section, we have provided a consolidated structural introduction to be followed by a therapeutic 
organization, which brings together structure, mechanism and biology under specific disease/biology 
subsections. We have made an attempt to track disease indications associated with the range of structural 
modifications in the hope that this overview may serve as a useful basis for further analog development. 
3. Inflammation Control in Vitro and in Vivo by MACs 
In general, the anti-inflammatory activity of curcumin analogs results primarily from inhibition of 
nuclear factor kappa-B (NF-κB), tumor necrosis factor (TNF)-α, and interleukin (IL)-6, NF-κB being  
a key transcriptional factor in the inflammatory signaling pathway. Many studies have reported that 
MACs may target both inflammation and tumors by inhibiting the activation of NF-κB [8,23,60–74]. 
The anti-inflammatory properties and the ability to inhibit the immune response by MACs, at least in 
part, result from inhibition of the activation of the latter multi-protein complex, since many of the genes 
that are implicated in the immune/inflammatory response are upregulated by NF-κB. MACs have  
also been shown to be a direct inhibitor of enzymes that are important in the inflammatory response, 
including lipoxygenase (5-LOX) and cyclooxygenase (COX-2) [75]. With few exceptions, most of the 
curcumin analogs with good anti-inflammatory action incorporate the diarylpentanoid linker instead of 
the β-diketone moiety and incorporate heteroatom and halogen moieties (17–25, Figure 5). Parallel 
studies have also confirmed that these analogs exhibit better anti-tumor, anti-inflammatory and  
anti-oxidant activity relative to curcumin (17–19, 26–29, Figure 5). 
















































Figure 5. Structures of anti-inflammatory MACs 17–29. 
3.1. NF-κB/TNF-α 
Our group has synthesized two structurally similar analogs, 3,5-bis-(2-fluorobenzylidene)-4-piperidone 
(6, EF24) and 3,5-bis-(2-pyridinylmethylidene)-4-piperidone (7a, EF31) and compared their NF-κB 
inhibition activities in mouse RAW264.7 macrophages [61] Results showed that 7a (IC50 ~ 5 μM) 
exhibits significantly more potent inhibition of lipopolysaccharide (LPS)-induced NF-κB DNA 
binding compared to both 6 (IC50 ~ 35 μM) and curcumin (IC50 > 50 μM). Compound 7a also 
effectively blocks NF-κB nuclear translocation and the induction of downstream inflammatory 
mediators including pro-inflammatory cytokine mRNA and protein (TNF-α, IL-1β and IL-6). 
Furthermore, 7a (IC50 1.9 μM) shows significantly greater inhibition of IkB kinase β compared to 6 
(IC50 ~ 131 μM). In addition to these efforts, Vileker et al. conducted a series of studies demonstrating 
the effectiveness of 6 to block mRNA synthesis of NF-κB dependent inflammatory factors [64]. 
Liang et al. reported a series of MACs (30–40, Figure 6) with the ability to inhibit LPS-inducing 
macrophages that release inflammatory cytokines TNF-α and IL-6 via in vitro cell experiments [65,66]. 
Systematic structure-activity relationship studies on these compounds showed that multiple analogs 
can block expression of the inflammatory factors. Cyclohexanone-containing derivatives are somewhat 
more effective than acetone or cyclopentanone-derived compounds [65]. Installation of a long chain 
substituent such as 3-(dimethylamino) propoxyl (compound 40) shows an inhibitory effect on LPS-induced 
TNF-α expression similar to curcumin, but a more potent inhibitory effect on LPS-induced IL-6 
expression than curcumin. However, the dimethylamino-analogs 41–43 (Figure 7) exhibit either 
similar or reduced inhibitory effects on LPS-induced TNF-α or IL-6 expression relative to curcumin, 
indicating that nitrogenous substitution by itself does not enhance anti-inflammatory activity. On the 
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other hand, 33 and 44 (Figures 6 and 7) with a long chain allyloxyl moiety shows a stronger inhibitory 
effect on LPS-induced TNF-α indicating that the length and flexibility of the distal substituents may be 
















































Figure 6. Structures of anti-inflammatory MACs 30–40. 
Among curcumin-like compounds, 30, 31, and 45 (Figures 6 and 7) deliver the best inhibition 
activities while 46, 47, and 48 (Figure 7) are essentially inactive, suggesting that the presence of  
a 3-methoxy group in combination with the 4-OH group is critical to activity. The electronegative 
property of a substituent in the 4’-position plays an important role in anti-inflammatory activities [66]. 
Compounds without a para substituent in the phenyl rings show little inhibitory activity, whereas the 
presence of electron-withdrawing chloro substituents removes the anti-inflammatory activity completely 
(49–52, Figure 7). By comparison, tetra-methoxy 53 or tetra-methyl 54 (Figure 7) with 4’-substitution 
showed significant inhibitory activities against LPS-induced TNF-α and IL-6. These results indicate 
that the anti-inflammatory activity induced by LPS may be associated with the electronegativity of  
4’-substituents. Electron-donating capacity from this position may increase the anti-inflammatory abilities, 
whereas a neutral and electron-withdrawing moiety may reduce or remove such bioactivity. Among all 
the compounds studied, 40 and 44 showed the highest potential as anti-inflammatory agents. However, 
the underlying molecular mechanisms of N-substituted long-chain substituents at the transcriptional or 
post-transcriptional levels are yet to be determined. One possible origin of the substituent-influenced 
inflammatory variation may be the enhanced resonance interaction of electron-donating functionalities 
with the enone group so as to attenuate its electrophilic properties. Since thiol conjugation appears to 
be a critical feature for biologically active enones [76,77] perturbation of the Michael addition for 
MACs by para-substituents may have a decisive influence on the degree of anti-inflammatory action. 
In mouse primary peritoneal macrophages, 55 (Figure 7) potentially inhibited the production of  
pro-inflammatory gene expression including TNF-a, IL-1b, IL-6, iNOS, COX-2 and PGE synthase. 
This activity was ascribed in part to the inhibition of ERK/JNK phosphorylation and NF-κB activation. 
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Compound 55 likewise shows significant in vivo effects on pro-inflammatory cytokine production in 
plasma and liver; namely, attenuated lung histopathology and reduced mortality in endotoxemic  
mice [67]. In LPS-challenged mice, pretreatment by 56 (Figure 7) attenuated the increase of plasma 
levels of NO, TNF-α and IL-6, while significantly reducing the hepatic inflammatory gene transcription 
by the inhibition of various inflammatory mediators [68]. Compounds 57 and 58 (Figure 7) significantly 
alleviate renal and cardiac injuries in diabetes mellitus by means of an anti-inflammatory  
mechanism [69,70]. Further studies revealed that these anti-inflammatory actions are mediated by 
inhibiting the JNK/NF-κB signal pathway [67,69,71]. The Liang group has reported that, in general, 
the six-membered cyclohexanone ring system (IC50 values from 4 to 180 µmol) is superior to the  
five-membered cyclopentanone system (IC50, 1 to 222 µmol) for inhibitory activity [8]. The difference is 
often modest, but can be significant depending on the cell line used for the comparison. Some of 
analogs screened by Liang et al. have undergone preclinical study for the treatment of arthritis, pyemia 


























































Figure 7. Structures of anti-inflammatory MACs 41–58. 
Weber et al. studied the inhibition of TNFα-induced activation of NF-κB by dienone MACs (17, 19, 
27, 28, 59, Figures 5 and 8) by using the Panomics’ NF-κB Reporter Stable Cell Line [72]. The enones 
tested included analogs with both a 5-carbon spacer (17, 26, 30, 60–62, Figures 5, 6 and 8) and a  
3-carbon spacer (63, Figure 8) separating the aromatic rings. The former are highly active and include 
cases with heterocyclic rings such as 17 (IC50 = 3.4 µM), the most active agent among the tested 
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enones. While these compounds retain the enone functionality, their NF-κB inhibition does not 
correlate with their anti-oxidant activity. The study revealed that prevention of stress-induced 
activation of NF-κB by MAC analogs was achieved by inhibition of specific targets rather than by an 
overall anti-oxidation process. The latter action by MACs depends on the ability to quench free radical 
reactions, but can be complemented by inhibition or inactivation of specific targets. Researchers have 
tested the abilities of MACs to quench the pre-formed radical monocation of 2,2'-azinobis-(3-
ethylbenzothiazoline-6-sulfonic acid), known as the total radical-trapping anti-oxidant parameter 
(TRAP) assay, and their ability to reduce the ferric tripyridyltriazine complex, namely the ferric 
reducing/antioxidant power (FRAP) assay [78]. Most active analogs probed in this study (17, 19, 28) 
show no activity in the TRAP or FRAP assay, which led to the conclusion that there is no correlation 
between anti-oxidant activity and inhibition of the TNFα-induced activation of NF-κB. This lack of 







































































Figure 8. Structures of anti-inflammatory MACs 59–73. 
Yadav et al. synthesized the series of heterocyclic cyclohexanone analogues 22, 20–25, 65–67 
(Figures 5 and 8) which were screened for inhibition of NF-κB transactivation in non-adherent leukemia 
cells [73]. The pyridine heteroaromatic substituted bis-methylene cyclohexanones 22 and 23 were  
the most active heteroaromatic analogues (IC50 = 1.0 µM and 0.8 µM), while the corresponding  
five-membered heteroaromatic agents exhibit considerably less activity (e.g., 36, IC50 = 34 µM).  
The polymethoxyphenylmethylene N-methylpiperidone derivatives 66 and 67 (Figure 8) reveal good 
activity (IC50 = 0.9 and 4.0 µM, respectively) in the luciferase assay compared to the cyclohexanone 
core derivatives (~30 fold less activity), which had no activity. These results suggest that in addition  
to the electronic effects of substituents on the terminal aromatic rings described above, a nitrogen 
heteroatom in the aromatic rings or heteroatoms in the core cyclic ketone enhance potency. Cao et al. 
Molecules 2015, 20 260 
 
 
have reported pyridinyl analogs of dibenzylideneacetone (68, 69, Figure 8), and these MACS were 
evaluated for their anti-inflammatory activity by the NF-κB inhibition assay in colorectal carcinoma 
cells [74]. Almost all synthesized analogs exhibited better cytotoxicity than curcumin, and 68 in 
particular delivered the highest anti-NF-κB (IC50 = 0.52 µM) potency in suppressing growth of colon 
cancer cells (IC50 = 1.6 µM). 
Recently, Liu et al. synthesized a series of allylated or prenylated MACs and evaluated their  
anti-inflammatory effects in RAW 264.7 macrophages [79]. A majority of the compounds effectively 
inhibited the LPS-induced expression of TNF-α and IL-6. The preliminary and quantitative SAR 
analyses showed that the asymmetric MACs possess higher anti-inflammatory activity than symmetric 
analogs, and suggested that the electronegativity and molecular polarizability of the MAC structures 
are important for the inhibition of LPS-induced IL-6 expression. Among the tested compounds, 82–85 
(Figure 9) exhibited stronger inhibition of both TNF-α and IL-6 than curcumin. In particular, 83 
delivered the most potent effects with inhibitory rates reaching 68% and 91%, respectively, and 
exhibited significant protection against LPS-induced death in both septic mice models and primary 
peritoneal macrophages. A related and recent report described the synthesis and evaluation of various 
asymmetric MACs as anti-inflammatory agents by inhibiting the LPS-induced secretion of TNF-α and 
IL-6. Among the test subjects, 86–90 exhibited dose-dependent inhibition. The anti-inflammatory 
activities of analogs 86 and 87 were associated with inhibition of the phosphorylation of the 


































































































Cyclovalone (91) and three analogs (92–94) incorporating the diarylpentanoid linker between the 
terminal phenyl rings show anti-COX activity. The dimethylated analogs 92 and 94 are more potent 
than 95 and 97 that are, in turn, more potent than curcumin, suggesting the addition of methyl groups 
on the phenyl rings enhances anti-COX activity [80]. 
A series of MACs 70–79 (Figures 8 and 9) containing a variety of heterocyclic rings (the indolyl, 
imidazolyl and thienyl rings) was synthesized by Katsori et al [75] and investigated for their ability to 
inhibit the inflammation related enzymes 5-LOX and aldose reductase (ALR2). Results of these 
studies revealed that 71 and 79 are more potent inhibitors of inflammatory enzymes 5-LOX and ALR2 
than curcumin. Compounds 75 and 76 containing bromobenzene or heterocycles exhibit a high in vivo 
anti-inflammatory activity assessed by using the functional model of carrageenin-induced rat paw 
edema (expressed as percent inhibition of carrageenin-induced inflammation), while 75 showed much 
higher efficacy than indomethacin.  
Gafner et al. designed and synthesized MACs (59, 80) for inhibition of COX-1 and COX-2 and tested 
them in murine macrophages. Fluoro substitution in the MACs cyclohexanone analog 80 (Figure 9) 
enhanced anti-inflammatory activity, while nitro and tert-butyl substitution decreased it [81]. Based on 
COX-2 inhibition, 59 (IC50 = 5.5 µM) is more effective than other derivatives as well as curcumin 
(IC50 = 15.9 µM). The data suggests that structural elements responsible for COX-1 and COX-2 
inhibition do not correlate well with those responsible for inhibiting COX-2 and iNOS gene 
expression. However the same elements do contribute to inhibition of 12-O-tetradecanoyl-13-acetate 
(TPA)-induced ornithine decarboxylase (ODC) activity. TPA-induced ODC is a rate-limiting enzyme 
process in the polyamine biosynthetic pathway. Certain polyamines are known to be important for cell 
growth and differentiation and have been implicated in the early phase of tumor promotion. Thus, 
diminishing ODC activity has been used frequently as a marker for inhibition of tumor promotion. 
Weber et al. reports highlight MAC analogs 17 (IC50 4.1 μM) and 81 (IC50 3.8 µM) as potential  
COX-2 inhibitors, which imply an important role in pro-inflammatory stimulation via TPA-induced 
activation of AP-1 [82,83]. 
In general, the position and electronegativity of substituents on the terminal aromatic rings and the 
length of the spacer between these rings determine the anti-inflammatory activities of MAC’s. For 
example, bromo substitution at the 2-position (compound 58) shows little activity, whereas substitution 
at the 3-position results in superior anti-inflammatory activity compared to curcumin (IC50 10–20 µM). 
MACs incorporating the cyclohexanone moiety are reported to be slightly more effective than those 
with acetone and cyclopentanone as the central core of the molecules [84]. Analogs bearing a long 
chain allyloxy substituent (40, 55, 56) exhibit enhanced activity, while analogues with dimethylamino 
or trifluoromethane substituents reveal diminished activity. Analogs possessing 3-methoxy (30, 31, 45) 
or trimethoxy (66) substitution display higher activity than curcumin. Heteroaromatic ring-substituted 
MACs (17, 18, 21–25) also show moderate anti-inflammatory activity [65,72,83,84]. All of these 
effects have their counterparts in the action of MACs in vitro in tumor cells and in vivo in murine 
models. The complementary actions of ablating both inflammation and cancer have their origin in 
blocking the same set of cell signaling pathways. This phenomenon is explored in detail in the next 
section addressing the action of MACs in the cancer environment. 
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The astute reader may note that several reports cited in this section highlight the influence of 
electronegative substituents at the para-positions of the MAC terminal aromatic rings as a mediator of 
anti-inflammatory activity. This point arises from the intuitive observation that electron-donating 
substituents appear to decrease inflammation, while electron-withdrawing groups are less effective or 
eliminate it [28,66,84]. The productive use of electronegativity descriptors in QSAR correlation 
treatments is consistent [79]. These works do not, however, provide a qualitative rationale for how 
differential electronegativity might be exerting the proposed effect. Prompted by a Reviewer, we 
propose the phenomenon to be complex and composed of several reinforcing forces. The following 
Figure 10 suggests the interplay of some of them. 
 
Figure 10. Electrostatic potentials for a series of piperidinone analogs with para-substituents 
H, CH3, OCH3, OH, F and CF3 situated at the purple centers; charges: green/neutral, 
red/negative and blue/positive; surfaces generated with the semiempirical PM3 method in 
Student Spartan [85]. 
For substituents H and CH3, apart from the C=O moiety, the molecular surface is neutral, but the 
methyl groups of OCH3 begin to exhibit slight positive charge in the molecular view shown. This is 
enhanced by OH substitution and further magnified across the entire molecular surface for F and CF3. 
These changes in electrostatic potential contribute to the binding of these molecules to the protein 
targets in the body’s cells. This is clearly not the whole, picture, however, since the protein binding 
pockets also need to accommodate the steric bulk of the p-substituents. In addition the OCH3, OH, F 
and CF3 groups must be compatible with any H-bonding or complementary electrostatic interactions of 
the MACs within reach at the binding center. Consequently, the charge distributions induced by the 
different electronegative atoms or groups partner with atomic size and non-bonded contacts to provide 
the maximum binding arrangement and, thereby, result in the associated ligand-protein affinities. 
These, in turn, undoubtedly modulate the strength of the ultimate anti-inflammatory output at the 
terminus of a long train of linked intra- and intercellular physiological events. For now, the latter 
remain a mystery yet to be unraveled. 
H CH3 OCH3 
OH F CF3 
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4. Cancer Mediation in Vitro and in Vivo by MACs 
4.1. In Vitro Probes of Cancer Cell Lines and Signaling Factors 
The major actions of MACs reported in the anticancer literature are mainly anti-angiogenic and 
cytotoxic/anti-proliferative in the context of in vitro assays. These two phenomena correlate well, 
suggesting that the same signaling pathways or proteins are involved in the inhibitory processes. Not 
surprisingly, the same mechanistic factors may also be involved in the inflammatory events described 
in the previous section. However, unlike studies in inflammation research, investigators in cancer have 
most frequently evaluated MAC curcumin analogs in phenotypic assays, such as proliferation and 
angiogenesis, rather than mapping signaling pathways or identifying specific protein targets. Curcumin 
is, of course, the exception. A recent review on breast cancer by Cridge, Larsen and Rosengren 
summarizes associated molecular targets and points out the intervention of cytokines, growth factors, 
apoptosis and cell cycle proteins in addition to transcription factors and enzymes for a subset of  
MACs [32]. A recent modest kinase screen demonstrated that one MAC, EF31 (7a = 14, X = NH,  
Y = N, Figure 2), is able to block 22 of 50 cancer-related kinases and suggests a mechanism dominated 
by competition with ATP [26]. Clearly more work needs to be done in this area, but it is highly likely 
that a majority of intracellular pathways established for curcumin will be followed by the MAC class 


























































Figure 11. Structures of anti-cancer MACs 95–103. 
For example, Dimmock and colleagues synthesized a series of symmetric piperidones (95–118, 
Figures 11 and 12) and used murine P388 and L1210 cells as well as human Molt4/C8 and CEM T 
lymphocytes to evaluate cytotoxic effects [86,87]. The average IC50 values for the N-acryloyl analogs 
104–110 for the four cell lines was 1.8 μM, while the N-unsubstituted compounds 111–117 delivered  
a considerably higher average of 44 μM. Thus, within this series of substances, the N-substituted analogs 
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furnish considerably greater cytotoxicity, and the SAR correlates positively with the size of the aryl 
substituents. However, in the three clusters of agents investigated, the SARs are specific to each series. 



























































Figure 12. Structures of anti-cancer MACs 104–126. 
Adams et al. synthesized a separate series of MACs and screened them for anti-proliferation and 
anti-angiogenic activity. Analogs 6 (EF24), 119, 120 and 121, among others, exhibited excellent 
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were also efficacious in anti-angiogenisis assays. For example, 6 is almost as potent as TNP-470, 
which has undergone clinical evaluation as an anti-angiogenic drug [23]. These data suggest: (1) The 
symmetrical α,β-unsaturated ketone moiety installed in the analogs shows increased anti-cancer and 
anti-angiogenesis activity compared with the β-diketone structure of curcumin; (2) Ortho-substitution 
on aromatic rings (119–121, Figure 12) in some cases enhances the activity for symmetrical analogs, 
the meta- or para-substitutions (124, 125, Figure 12) being somewhat less active possibly due to 
alterations in molecular geometry (Figure 4); and (3) Introduction of a heteroatom in the cyclic ketone 
(120, 121 and 126, Figure 12) generally yields improved anti-cancer and anti-angiogenic activity. 
Compound 6 (EF24) was further studied by Thomas et al. and found to decrease cell viability of 
lung cancer cells via upregulated mitogen-activated protein kinases (MAPK) as evidenced by 
increased ERK1/2, c-Jun N-terminal kinase (JNK) and p38 (stress-activated protein kinase) 
phosphorylation [62]. A synergistic effect between the P38 inhibitor and 6 with respect to clonogenic 
activity of A549 lung cancer cells and apoptosis induction was also reported. Another interesting 
observation for 6 was revealed in relation to its anti-hypoxia inducible factor (HIF)-1 activity 
compared to curcumin. While curcumin inhibited HIF-1α gene transcription, 6 inhibited HIF-1α  
post-transcriptionally. The inhibition phenomenon occurred in a von Hippel Lindau (VHL)-dependent, 
but proteasome-independent manner. An additional difference was that curcumin induces microtubule 



















































































Figure 13. Structures of anti-cancer MACs 127–148. 
To evaluate MAC effects on colon cancer cells, Ohori et al. synthesized and screened 127–131 
(Figure 13) against cell growth. The analogs are symmetrical 1,5-diarylpentadienones, the aromatic 
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rings of which possess alkoxy substituents at meta- or meta/para-positions. Compound 128 was found 
to exhibit four-times higher potency than curcumin (IC50 2 µM vs. 8 µM) [89]. 
Chandru and colleagues prepared the dienone cyclopropoxy curcumin analogs 132–135 (Figure 13) 
and evaluated the quartet by anti-proliferation and anti-angiogenic assays employing an in vivo Ehrlich 
ascites tumor mouse model. The agents significantly reduced ascite volumes accompanied by 
increased apoptosis. Anti-angiogenic activity was demonstrated by the significant reduction of 
microvessel density in the peritoneum wall sections. The study was interpreted to imply that the two 
aromatic regions might be critical for potential drug-protein interactions [90]. 
Aromatic enone and dienone analogues (136–144, Figure 13) were prepared by Robinson et al. and 
screened in an in vitro anti-angiogenic assay [91]. The compounds inhibited cell proliferation, 140 and 
143 being particularly potent, suggesting the importance of heterocyclic substitution. The same group 
subsequently generated derivatives differing in either the substitution pattern of the benzene rings or 
the fusion characteristics of the aromatic rings. The most notable compounds 145–148 (Figure 13) are 
tetralones which introduce a measure of rigidity by tethering the central enone moiety. The 2-naphthyl 
analog 146 exhibits the best anti-angiogenic activity, 85% at 1 µg/mL in the following sequence:  
146 > 147 > 145 > 148 [92]. 
Woo et al. conceived a series of asymmetric MAC chalcones by pairing substituted phenyl amides 
with the terminal curcumin styrene unit carrying m-OMe and p-OH; i.e., 149–162 (Figure 14).  
The in vitro growth inhibition of human umbilical vein endothelial cells (HUVEC) caused by 149, 
158, 161 and 162 reflects potent anti-angiogenic activity and suggests it may be particularly important 













































































































Figure 14. Structures of anti-cancer MACs 149–162. 
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Jha et al. synthesized a series of highly polar MACs 163–179 (Figure 15) by replacing the unstable 
keto-enol moiety of curcumin with a substituted piperidone and testing the series against tumor 
inhibition activity [94]. In human Molt 4/C8 cells and CEM T-lymphocytes, compounds 171–179 were 
significantly more potent than the control agent melphalan [95] in inhibiting leukemia and colon 
cancer cell lines. However, compounds 163–170 lost activity. The change in potency is undoubtedly 
due to the geometric disposition of the double-bond configuration within the (O=C)-CH=CH-(C=O) 
moiety of the piperidone substituent; i.e., E vs. Z stereochemistry. The most likely planar E form is 
expected to be twisted out of planarity in the Z isomer by steric effects encountered from the syn olefin 
orientation. The corresponding X-ray structures would offer deeper insights into this hypothesis, but in 
the spirit of the message of Figure 4, we presume that co-planarity of the compounds plays a key role 















































































































Figure 15. Structures of anti-cancer MACs 163–179. 
Fuchs et al. synthesized a collection of largely acyclic MACs 180–192 (Figure 16) and tested their 
anti-tumor properties by blocking the proliferation of prostate and breast cancer cells [96]. Compound 
188, decorated with three methoxy groups at ortho and para terminal ring sites, is particularly 
attractive with an IC50 within the 10−6 M range corresponding to an inhibitory potency of more than 
50-fold higher than curcumin. Suarez and colleagues prepared a similar subset of compounds 61, 180, 
181, 191 and 192 (Figures 8 and 16) and tested them against several tumor cell lines [97]. All the 
compounds exhibited different degrees of inhibitory activity against colon cancer cells HT-29, but 
analogs 61, 180 and 181 furnished superior potency (IC50 < 2.3 μM). 
Yamakoshi et al. reported the cytotoxicity of MACs 193–205 (Figure 17) to the human colon 
cancer cell line HCT-116 [98]. SAR analysis complemented other studies by highlighting the structural 
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motifs for bis-(arylmethylidene)acetone and 3-oxo-1,4-pentadiene and the degree of substitution as 
being important for maintaining high levels of cell cytotoxicity. Interestingly, the compound structures 
studied in this work suggests that the symmetry of the compounds is relatively insignificant for 
cytotoxicity. Zhang and co-workers prepared 26 asymmetric monocarbonyl analogs and demonstrated 
that five of them strongly inhibit the release of tumor necrosis factor-α and interleukin-6, while also 
showing much higher chemical stability than curcumin itself [28]. Thus, while the compounds are 
certainly suitable for use as agents against acute inflammatory disease, it remains to be seen whether 
the additional synthetic steps and the low-to-modest yields in some cases justifies the asymmetry. 
Liang’s team likewise tested a series of MACs for the anti-tumor activity and presented an SAR that 
implied compounds such as 206 and 207 (Figure 17) can induce tumor cell apoptosis by activating the 
stress mechanism of endoplasmic reticulum [99,100]. The two compounds have been reported to be 
































































Figure 16. Structures of anti-cancer MACs 180–192. 
Other curcumin analogs, such as 30 (Figure 6) and 208 (Figure 17) also inhibited phosphorylation 
of STAT3 in breast and prostate cancer cells. In addition, these analogs exhibited more potent 
activities than curcumin on the down-regulation of signal transducer and activator of transcription 
(STAT3), AKT, and HER-2/neu, as well as the inhibition of cancer cell growth and migration [101,102]. 
Malhotra and Rawat et al. reported a series of novel 3,5-bis(arylidene)-4-piperidone-based 
symmetrical MACs and screened them for their potential anticancer activity. Among reported 
compounds, 209 and 210 (Figure 17) showed significant inhibition against various human tumor cell 
lines. Mechanism studies with the COLO 205 cell line suggests that compound 209 activates both 
caspase 8 and 9 and moderately activates effector caspase 3, which combined with the DNA 
fragmentation event suggests an apoptotic mechanism. Compound 210 delivers the characteristic 
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annexin positive result, DNA fragmentation and caspase 3 activation. The activation of caspase 8, but 























































































































Figure 17. Structures of anti-cancer MACs 193–210. 
More recently, compound 211 (Figure 18) was subjected to HUVEC in vitro assay and shown to 
elicit anti-angiogenic activity by suppressing the downstream protein kinase activation of vascular 
endothelial growth factor (VEGF) via decreasing phosphorylation of AKT and p38 [104]. The same 
group reported that 212 displays an anti-tumor effect in the MTT cell proliferation assay using a H460  
non-small cell lung cancer cell line [105]. 
A Guangzhou-New Jersey collaboration has reported in vitro activity for two series of analogs, the 
thiopyran-4-ones 213–216 [106,107] and the benzyl piperidones 217–219 [108] (Figure 18). The 
thiopyranones were tested in an MTT proliferation assay against prostate PC-3, HT-29 colon and  
Panc-1 cancer cell lines and shown to deliver suppressive IC50 values < 1 μM. All block transcriptional 
activity of NF-κB, modulate phosphorylation of ERK1/2 and reveal potent stimulation of apoptosis. 
The compounds are also uniformly 10–40 fold superior to curcumin in growth inhibition assays. In the 
parallel study with the benzyl piperidones 217–219, PC-3, pancreas BxPC-2, HT-29, and H1299 lung 
cancer cell lines were probed with growth inhibition, MTT and trypan blue exclusion assays. The 
compounds are active with IC50 values < 2 μM and, similar to the thiopyranones, cause apoptosis in 
PC-3 cells by reduction of phosphorylation of ERK1/2 and AKT. Utilization of the benzyl moiety as a 
linker, the introduction of F and OCH3 substitution on the benzyl aromatic ring and increase of steric 
bulk appears to enhance the cytotoxicity. A final investigation by Samaan et al. [109] presented a  
Molecules 2015, 20 270 
 
 
32-compound series of nitrogen-containing heterocyclic derivatives represented by 220–222 (Figure 18) 
as a challenge against the h-androgen independent prostate cancer cell lines PC-3 and DU-145. The 
analogs are reported to furnish anti-prostate cytotoxicity IC50 values of 50–390 nM, but no toxicity 
against MCF-10A normal mammary epithelial cells. The terminal 5-membered ring heterocyclic 
molecular class (220–221) would appear to serve as an effective bio-isostere of the now well-recognized 
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Figure 18. Structures of anti-cancer MACs 211–222. 
4.2. In Vivo Cancer Models, Tumor Growth and Regression: MACs 
It is often the case that an apparently exciting in vitro profile proves to be ineffective in an animal 
model. As a result, the cell-based outcomes described in the previous two sections and those below 
require in vivo complementation. To date, a number of rodent models have been reported. One of the 
earliest by Shoji et al. involved treatment of athymic nude mice carrying MDA-MB-231 breast cancer 
solid tumors with EF24 (6) [23]. Significant anti-tumor effects were observed at 20 mg/kg with a 30% 
reduction of tumor weight to control. At 100 mg/kg, the tumor weight dropped to 55% without harmful 
side effects; namely liver, kidney and spleen toxicities were absent, and the mice experienced normal 
weight gain. The maximum tolerated dose (MTD) of 200 mg/kg i.v. indicated that in this setting 6 
appears to be considerably more effective and substantially safer than the clinical drug cisplatin  
(MTD = 10 mg/kg i.p.). Perturbation of the same cell line with 6 demonstrated cell cycle arrest in  
the G2/M phase, an increase in intracellular ROS levels [67] post-transcriptional inhibition of the  
pro-angiogenic transcription factor HIF-1α, unlike curcumin, induction of microtubule stabilization in 
cells [87]. In a parallel study by the same group [110] coagulation factor VIIa (fVIIa) was employed as 
a carrier to deliver EF24 to tissue factor (TF) on the surface of the cancer cells, significantly 
decreasing the viability of TF-expressing MDA-MB-231 and HUVEC cells. Subsequent i.v. 
administration of the EF24-FFRck-fVIIa conjugate to human breast cancer xenografts in athymic nude 
mice leads to complexation of the conjugate to TF, endocytosis of the complex and presumed 
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hydrolysis of the drug within the cytoplasm. The internally sequestered EF24 induces apoptosis and 
significantly reduces tumor size by comparison with systemically distributed and unconjugated EF24. 
By conjugating potent and toxic drugs to fVIIa, this targeted drug delivery system has the potential to 
enhance therapeutic efficacy in breast cancer and possibly other cells, while reducing toxic side effects 
by a combination of anti-angiogenic and anti-cancer actions. 
Similar encouraging results for EF24 (6) have been observed in the recent past for both 
subcutaneous and orthotopic hepatocellular carcinoma (HCC) models [111]. DU145 prostate cancer 
xenografts in immunocompromised mice [112] energy metabolism and ovarian cancer metastasis 
models [113] ovarian carcinoma xenografts [114] and potent growth inhibition (GI50) of a HCT-116 
human colon tumor xenograft in mice with little apparent toxicity [115,116]. As a companion to these 
murine studies, comprehensive pre-clinical mouse pharmacokinetics and metabolism have been 
performed for EF24 (6) by application of an LC/MS/MS assay [18]. The compound is stable in human 
and rat plasma at 37° for over two days and over a month at −20 °C. Protein binding in human, dog, rat 
and mouse plasma was >94% for all concentrations, albumin in human plasma being the primary 
target. EF24 pharmacokinetics in male CD2F1 mice were carried out at 10 mg/kg by i.v., i.p. and oral 
administration and best fit to a 3-compartment model. Terminal elimination half-life was 74 min 
accompanied by rapid absorption after oral administration, while i.v. dosing delivered a peak plasma 
concentration of 2.5 μM well above the in vitro GI50 value for sensitive cell lines in the NCI 60 cell 
line screen. Metabolism was monitored with liver microsome preparations and shown to be dominated 
primarily by NADPH-dependent reductive metabolism with a contribution from aromatic ring 
hydroxylation in the human fractions. A related liver microsome study for 7 (UBS109) reveals that 
reductive metabolism is also the primary deactivating mechanism, and that the primary metabolite with 
a single reduced C=C bond retains ~20% of the activity of 7 [19]. The high oral bioavailability of 6  
(35 and 60% after i.p. and oral administration, respectively) contrasts markedly with the extremely low 
value for curcumin in both rodents and humans. These features, along with the potent cytotoxic 
activity, were interpreted to suggest that EF24 (6) is a promising candidate for cancer drug 
development. Closely related analogs of EF24 (6) in which the terminal aromatic rings are replaced by 
pyridine rings, namely EF31 (7a) and UBS109 (7b) (Figure 2), both supplement and confirm the 
present observations for a range of other cancer types and for inflammation as well. A comparative 
study examined the effects of the two analogs on human head and neck squamous cell carcinoma 
(SCC) Tu212 xenograft tumors established in athymic nude mice. The more soluble and more 
effective EF31 provided a dose response at 15 and 25 mg/kg i.p. and average AUC(0–∞) values of 
3386 and 7769 h × ng/mL, respectively [12]. UBS-109 likewise delivers a dose response at 50, 100, 
and 150 mg/kg p.o. on SCC Tu212 xenografts, and 10 and 20 mg/kg i.p. on human pancreatic 
carcinoma Mia-Paca xenografts in athymic nude mice [14]. 
Separate investigations have examined bone mass loss in connection with metastatic breast cancer. 
Initially, curcumin, EF31 and UBS109 were compared for their relative effects on osteoblastogenesis 
and osteoclastogenesis in vitro. EF31 and UBS109 revealed a suppressive effect on osteoclastogenesis 
relative to curcumin, while UBS109 (7b) has a unique stimulatory effect on osteoblastic differentiation 
and mineralization associated with Smad signaling. 7b also potently inhibits NF-κB, which plays a 
pivotal role in osteoclastogenesis [117]. In a follow-up, UBS109 (7b) was examined for preventive 
effects on bone loss induced by breast cancer cell bone metastasis [118]. Nude mice were inoculated 
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with the corresponding cells into the head of the right and left tibia. Within a week, the mice were 
treated with control and UBS109 under both oral (50 or 150 mg/kg) and i.p. (10 or 20 mg/kg) 
administration once daily for 5 days/week for 7 weeks. X-ray diagnosis was used to ascertain 
remarkable bone loss in the untreated femurs and tibias. On the contrary, bone loss was prevented by 
both p.o. and i.p. treatment in the subject animals presumably by stimulating osteoblastic mineralization 
and suppressing osteoclastogenesis. The potential for human intervention resides in the possible 
control of breast cancer accompanied by parallel bone growth and restructuring. 
A particularly challenging condition without effective remedy is pancreatic cancer. An important 
mechanistic feature is aberrant DNA methylation, driven mainly by DNA methyltransferases. 
Accordingly EF31 (7a) and UBS109 (7b) have been probed for their ability to inhibit methylation in 
both in vitro and in vivo settings [14]. It is known that DNMT-1 is dependent on Hsp90 for activation 
and stability. Treatment of two pancreatic cell lines, Mia-PaCa-2 and PANC-1, with 7a and 7b resulted 
in inhibition of Hsp90 activity through its decreased binding to DNMT-1, decreased levels of Hsp90 
expression and the overexpression of three pivotal silenced genes commonly silenced in the spontaneous 
promotion of pancreatic cancer. Under in vivo conditions, Mia-Paca-2 xenografts were established in 
5-week old nude mice and treated with 25 mg/kg doses of 7a and 7b i.v. three times weekly for 30 
days. A panel of biomarkers was extracted from the tumors to show, among other things, that DNMT-1 
is clearly downregulated and associated with re-expression of the silenced genes. In addition, EF31 (7a) 
and UBS109 (7b) potentiate the inhibition of cell proliferation by oxaliplatin and 5-fluorouracil (5FU), 
two agents in common anti-cancer use in the clinic. A follow-up study reveals that these two compounds 
also exert an increased antiangiogenic effect on pancreatic cancer both in vitro and in vivo [119]. The 
unique properties of 7a and 7b appear to make them promising therapeutic agents for development in 
pancreatic cancer as single agents or as part of chemosensitized chemotherapy cocktails. 
Finally, two piperidines 22 (Figure 5) and 223 (Figure 19) assayed by Yadav and colleagues display 
the well-known inhibition of NF-κB activation complemented by substantial cytotoxicity towards 
MBA-MB-231, MDA-MB-468 and SkBr3 breast cancer cell lines; models for triple negative breast 
cancer disease [73]. Against the MBA-MB-231 cell line, the EC50 values are submicromolar at 0.8 and 




Figure 19. MACs 22 and 223 are effective in vitro against triple negative breast cancer. 
In a subsequent investigation, 22 suppressed the growth of MDA-MB-468 xenograft tumors by 
48% compared to control following 10 weeks of daily oral dosing (8.5 mg/kg) [120]. The compound 
also evidenced anti-angiogenic properties in vitro by inhibiting 46% of HUVEC cell migration and the 
induction of these cells to form tubular networks. Thus, 22 presents potent proapoptotic and  
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anti-angiogenic assets in vitro and in vivo, suggesting it to be a potential and promising remedy for 
treatment of ER-negative breast cancer. Other in vivo rodent studies not specifically reviewed here are 
likewise encouraging that the wide-ranging MAC family of anti-inflammatory and anti-cancer agents 
may well be able to address the corresponding debilitating conditions in humans sometime in the 
future [8,15–17,67,68,90,97,110,111,114,118]. 
5. Bacterial Growth 
Curcumin has received far less attention as inspiration for a potential antibacterial agent by 
comparison with its influence on the development of cancer blockers. This is surprising given that each 
year in the U.S. at least 2 million people become infected with bacteria resistant to antibiotics causing 
an annual death toll of approximately 23,000 arising directly from the infections [121]. The situation 
has become sufficiently dire that during the fourth week of September, 2014, President Obama has 
directed the CDC to create a national plan to control the situation [122]. Importantly, since 
inflammation follows infection as described in the previous section, were curcumin and mimics to 
become effective antibiotic agents, they offer an advantage in the ability to mediate simultaneously 
both bacterial titer and the inflammatory response. Early reports catalog curcumin’s blockade of 
various bacteria [123,124]. One recent study applied the molecule and its more soluble conjugate, 
curcumin glucoside, to two Gram-positive (Bacillus cereus, Staphylococcus aureus) and two  
Gram-negative (Escherichia coli and Yersinia enterocolitica) pathogenic bacteria. All four exhibited 
moderate growth inhibition in response to treatment by both molecules [125]. In a related study [126], 
it was noted that curcumin induces filamentation in Gram-positive Bacillus subtilis (strain 168), 
suggesting the molecule to be able to modulate bacterial cytokinesis (cell division to daughter cells). 
At the molecular level, the process is regulated by the assembly dynamics of FtsZ protein 
protofilaments, a protein aggregate that assembles into a ring at the future midpoint of bacterial cell 
division [127]. FtsZ is a prokaryotic homologue of the eukaryotic protein tubulin that regulates the 
function and trafficking of microtubules. Curcumin was shown to inhibit assembly in vitro, increase 
GTPase action and bind to the protein accompanied by perturbation of secondary structure. Such 
actions, lethal to the bacteria, provide a provocative mechanistic hypothesis for the action of the drug. 
These observations were followed by a docking study exploring the interaction of curcumin with the 
catalytic cores of the E. coli and B. subtilis FtsZ proteins [128] The tentative location of the binding 
site, supported by bacterial mutagenesis, was proposed as an opportunity to access novel inhibitors by 
structure-based molecular design [129–131]. 
Three interesting reports have explored MACs as candidates for bacterial control. An early 
exploration presented 40 compounds in the a, b and c classes shown in Figure 4 and compared their 
actions as monitored by zones of inhibition against seven multi-drug resistant bacteria containing both 
Gram-positive and Gram-negative examples [132]. A few members of each inhibitor class are very 
similar to the action of curcumin, but all are less potent than the β-lactam antibiotic ampicillin. 
Encouraging, however, most were found to be active against Enterobacter cloacae, an organism that is 
clinically resistant to ampicillin. On average, the acyclic a-class was claimed to be overall most 
effective, though the differences would appear to be small. Only one substitution offered a sizeable 
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ortho-substituent (Br). This member of each of the three classes proved to be inactive, perhaps due to 
steric distortion (cf. Figure 4). 
The second study prepared 15 piperidones and screened them against Salmonella typhi, Vibrio 
cholerea, Escherichia coli and Staphylococcus aureus [133] Several compounds produced significant 
zones of inhibition (e.g., 224, Figure 20) for the first two bacteria superior to the action of both curcumin 
and penicillin. More modest activity was observed for the other analogs against all four bacteria. 
224 225
Figure 20. MACs 224 and 225 block the growth of multiple bacterial strains in vitro. 
Finally, a very recent investigation explored the effects of EF24 (6 and 14, Y = C-F, X = NH) and 
its dimer 225 (EF2DTPA) against Gram-negative (Escherichia coli) and Gram-positive  
(Enterococcus faecalis, Staphylococcus aureus) bacteria [134]. Both classes experience direct bacterial 
growth suppression. Additional experiments demonstrated that the compounds do not influence 
bacterial uptake or localization in dendritic cells. Although the antibacterial potencies of the synthetics 
are considerably lower than that of traditional antibiotics, the authors suggest that such substances 
might be useful in combination with other chemopreventive agents in appropriate situations. 
Although the literature supporting the results discussed in this section have not explored the FtsZ 
connection, they clearly illustrate that MACs carry antibacterial activity and, in some cases, are 
effective against highly resistant bacteria. Considering the structural insights derived from examining 
the FtsZ-curcumin complexes [124]. it is likely that a similar evaluation of modeled FtsZ-MAC 
complexes would lead to suggestions for compound modification and drive investigations to confirm 
the prospective binding and lead to novel antibacterial candidates. 
6. Tuberculosis 
Tuberculosis (TB) is an airborne disease caused by the contagious and ancient bacterium 
Mycobacterium tuberculosis (M. tuberculosis). TB is considered latent when the M. tuberculosis 
infection is present but the immune system is able to prevent active multiplication. If the immune 
system is unable to prevent bacterial growth, TB becomes active and can be fatal, if untreated. About 
one third of the world’s population is infected with the microorganism. In 2012 there were nine million 
new cases and 1.3 million TB-related deaths around the world [135]. Not surprisingly, TB is the 
leading killer of people infected with immune compromised HIV, making TB one of the most deadly 
diseases in the world. Currently, ten drugs are approved by the FDA to treat active TB [136] with a 
combined success rate reported to be 87% in 2011 [137]. While current drugs are highly effective 
against the TB bacteria, drug-resistant strains are becoming more prevalent especially in less 
developed countries. Contemporary treatment methods for drug-resistant TB are less effective and 50 
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to 200 times more expensive than treatment for classic cases of TB [138]. As a consequence, discovery 
of alternative drugs is of high importance. 
Curcumin was reported to inhibit M. tuberculosis growth as early as the mid-twentieth century, 
making it an underexplored but promising drug candidate against TB. In 1949 Schraufstatter and 
colleagues reported that curcumin is able to completely block M. tuberculosis growth in vitro at  
a dilution of 1:40,000 [139] A recent review by Marathe and co-workers argues that curcumin may 
serve as an inhibitor against efflux pumps in TB bacteria. Efflux pumps mediate the efflux of 
antibiotics, drugs and other classes of compounds. Several studies indicate that efflux pumps are 
behind the survival mechanism for resistant M. tuberculosis [140–142]. Another investigation by Dube 
and colleagues used computational models to focus on a specific domain of an essential enzyme for  
M. tuberculosis (the BRCT domain) known as M. tuberculosis enzyme (MtuLigA) [143]. MtuLigA is 
essential and unique to TB bacteria, making it an intriguing drug target. Computational models 
suggested that a curcumin derivative, monoacetylcurcumin, binds to the BRCT domain, but no 
experiments were performed to confirm inhibition of MtuLigA by curcumin or its analogs. Takeuchi 
and co-workers conducted in vitro experiments to study the inhibitory activity of curcumin derivatives 
against DNA polymerase λ [144], which also contains the BRCT domain as part of its active site. 
Curcumin itself demonstrated strong inhibition of DNA polymerase λ (IC50 7.0 μM), while its 
monoacetyl derivative proved to be nearly twice as effective (IC50 3.9). Agrawal et al. reported that 
demethoxycurcumin (2) can block M. tuberculosis H37Rv strain with a minimum inhibitory 
concentration (MIC) of 200 μg/mL (5.8 × 10−4 M) [145]. Of four synthetic derivatives of 2, two 
analogs exhibited values of 125 and 8 μg/mL MICs. This compares with a rifampicin control at  
2 μg/mL. The latter most active compound carries an R = OCH2-CH=CH-CO2C2H5 p-substitution, 
while the former lacking a conjugated ester (R = OCH2CO2C2H5) is 16-fold weaker. Michael addition 
may therefore play an important role in the mechanism of such compounds. Bairwa et al. have recently 
reviewed a broader set of similarly substituted keto-enol curumin derivatives and drawn a similar 
conclusion [27]. Finally, while curcumin shows promising anti-TB activity in vitro, it fails to show 
similar effectiveness in vivo [146]. One wonders if the curcumin derivatives mentioned here would 
show the same fate. 
As previously stated, replacement of curcumin’s keto-enol functionality with a single carbonyl 
group may serve as a way to achieve greater stability and perhaps enhanced performance. MACs and 
related analogs have not been thoroughly explored at the time of writing, implying a potentially 
important direction for this class of molecules as anti-tubercular agents. Dimmock and co-workers 
have addressed this problem by combining the MACs architecture with a Mannich base and evaluating 
the compounds in vitro for antimycobacterial properties against M. tuberculosis H37Rv [147].  
At 12.5 ug/mL, the Mannich bases achieved 99% inhibition, while a related series of unsaturated 
ketones blocked microorganism growth by only 21%–66%. Two of the bases were both exceptionally 
active with MIC values of 0.39 ug/mL (226, second structure not shown), which compares very 
favorably with rifampin (0.16 uM/mL). A follow-up evaluation on 226 sought to understand the origin 
of the high activity by preparing the partial structures 227 and 228 (Figure 21) [148]. Compound 227 
proved to be essentially inactive, but 228 gave a moderate MIC value of 12.5 uM obviously 
highlighting the N(CH3)2 moiety. A probe of toxicity against Vero cells showed selectivity indices 
(IC50/MIC) for 226 and 228 to be 21 and 0.004, the former considered to signal a lead. Thus, enone 
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226 was evaluated against seven strains of M. tuberculosis including multidrug resistant (MDR) and 
extensively drug-resistant (XDR) strains to deliver MIC values across the board very similar to that of 
M. tuberculosis H37Rv. Accordingly, the drug-resistant strains do not evidence cross resistance to 
Mannich base 226, which appears to exert a different mode of antimycobacterial action relative to that 






























229 230  
Figure 21. Structures of various MACs serving as in vitro antimycobacterial agents against 
TB (226–230). 
A separate investigation focused on the preparation of a series of piperidones, which showed 
excellent in vitro antimycobacterial properties against M. tuberculosis H37Rv [149]. Among others, 229 
and 230 are 100% inhibitory at 6.3 μg/mL with MICs at 0.2 and 0.8 μg/mL, respectively. In addition, 
the compounds are generally well tolerated in mice as judged by toxicity and neurotoxicity screens. 
Oral and ip dosing of a selection of the piperidones in rats likewise failed to reveal neurotoxicity, 
although some swelling and stimulated respiration in rat liver mitochondria was observed. The two 
effects seem to be disconnected. Missing from this report is a study of the effects of the synthetic 
agents in animals infected by M. tuberculosis. 
More recently, EF24 (6), EF31 (7a) and UBS109 (7b) were examined for in vitro growth inhibition 
of both M. marinum and M. tuberculosis, including rifampicin-resistant strains [150]. The compounds 
deliver IC50 values in the 4-25 μM range, considerably lower than curcumin. An important mechanistic 
finding of this work is that the anti-mycobacterial action of the MACs appears to be dependent on 
Michael addition chemistry. 
We finish with a caveat. It has recently been shown that in a Drosophila model host system, host 
autophagy activation is essential for antimicrobial action against M. tuberculosis in adult flies [151]. 
Such activation would appear to be required for homeostatic control during chemotherapy against the 
TB microorganism. Blocking autophagy with antibiotics, i.e., with curcumin derivatives or MACs, 
might well compromise the host autophagy in the successful delivery of drug to M. tuberculosis during 
treatment. One of our MACs, EF25 (231, Figure 22), has recently been shown to block autophagy and 
contribute to cell death in a xenograft-based hepatocellular carcinoma study [152]. It remains to be 
seen whether the inhibition of autophagy by MACs in a cancer model would translate adversely to  
a TB model in which the drug would eliminate M. tuberculosis but simultaneously counter the effect 
by providing a safe haven for the microorganism during chemotherapy. 





Figure 22. A heterocyclic MAC that blocks autophagy (231). 
7. Alzheimer’s Disease 
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder that most often progresses to 
dementia for the aging population. It is estimated that 36 million people are afflicted by dementia 
worldwide with eight million new cases annually. The most common cause of dementia is AD 
accounting for 60%–70% of all such cases. While this obviously takes an irreversible toll on the 
recipient, AD also exacts a devastating price for families and caregivers [153]. The condition can be 
characterized in part by amyloid β (Aβ) aggregation, inflammation and oxidative damage in the brain. 
Unfortunately, not only are the pathological mechanisms not fully understood, no chemotherapeutic 
agents yet exists to either ameliorate or eliminate the illness. Curcumin, with its anti-oxidative and 
anti-inflammatory properties, is an under-explored but promising candidate for AD treatment. 
Recent studies indicate that curcumin or its analogs may be able to effectively address a wide  
array of AD symptoms [154]. In an early study conducted in 2004, curcumin was shown to bind to  
and inhibit the formation of Aβ oligomers and fibrils. In vitro experiments showed that curcumin 
inhibits Aβ aggregation more effectively than the over-the-counter NSAIDs ibuprofen and naproxen, 
anti-inflammatory drugs known to reduce amyloid formation [155]. In vivo experiments from the same 
study disclosed that curcumin injected peripherally crosses the blood-brain barrier, binds to plaques 
and reduces levels of amyloid aggregation in mice with advanced amyloid accumulation. The outcome 
is consistent with the hypothesis that fibrils and plaques are the cause of AD, and that they can be 
diminished in vivo. Accordingly, the authors suggested that curcumin should be taken to the clinic.  
A number of trials have been performed, and at the time of this writing (October, 2014) seven are 
underway [156,157]. Unfortunately, none have revealed a decisive counter to AD. In another 
subsequent study, a seven-day curcumin treatment regimen reduced levels of plaque by 30% in a 
mouse model of AD. The regimen also significantly reversed structural dendritic abnormalities. 
Curcumin was found to have limited effectiveness in crossing the blood-brain barrier, but results 
indicate a high affinity for Aβ that may contribute to the inhibition of amyloid formation [158].  
A molecular approach to understanding how small molecules interact with amyloid-β has generated  
X-ray structures of four compounds complexed with amyloid-like segments, the small molecules lying 
within cylindrical cavities running along β-spines of the fibers [159]. The electron density for 
curcumin at low resolution does not permit modeling in atomic detail, but it strongly suggests that the 
long axis of the molecule lies parallel to the fiber axis as it does for the other ligands examined. The 
work proposes a general pharmacophore for Aβ aggregates suggesting that mixtures of compounds 
may be necessary in any future treatment to address the collection of polymorphic aggregates that 
appear to characterize the amyloid fibrils. A separate analysis sought to determine the tautomeric form 
of curcumin binding to Aβ aggregates [160]. It was concluded that the keto-enol form is the dominant 
form associated with the latter and that targeting the enolization process might offer a target for design 
of novel amyloid-binding agents. However, observation of the enol form in the amyloid context is 
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entirely consistent with detailed examination of curcumin itself demonstrating the overwhelming 
presence of the keto-enol form [161], apparently eliminating the possibility to target tautomerization. 
While curcumin shows tantalizing effectiveness against AD, its low bioavailability and stability as 
discussed in the Introduction poses problems for its potential as a drug. As emphasized in previous 
sections, one way to bypass such characteristics is pursuit of curcumin analogs with more suitable 
biophysical and physicochemical properties. 
Orlando and co-workers [162] recently screened a library of curcumin derivatives and MACs with  
a novel ELISA-based assay that quantifies oligomeric Aβ peptide and distinguishes the oligomeric 
aggregate from fibrils. The work identified methylated curcumin 232 (Figure 23) as an oligomerization 
inhibitor (IC50 0.15 μM) with 6–7 fold improvement over curcumin (IC50 1.0 μM). MAC 233  
(IC50 0.8 μM) likewise proved nearly equivalent to curcumin by assay. In addition, a preliminary SAR 
provides some clues for future workers: (1) A least one enone group in the spacer between aryl rings is 
necessary to observe anti-Aβ aggregation; (2) Unsaturation in the linker is also required for inhibition; 
(3) Both methoxy and hydroxyl substitutions at the m- and p-positions elicit de-aggregation, a positive 
combination being a curcumin reversal (m-OH, p-OMe, 234 IC50 0.6 μM). It is interesting that the 
MAC variation 233 seems to offer little in the way of potency as it does for cancer and inflammation. 
A more elaborate SAR is likely to uncover improved and perhaps highly potent MAC candidates at 













232 233 234  
Figure 23. Potential oligomerization inhibitors against the Aβ peptide and fibrils (232–234). 
Oxidative stress is believed to be a major factor in the progression of AD by causing neurological 
degeneration and death [163]. An effective antioxidant against AD-related oxidative stress is an 
attractive strategy. An early study examined the antioxidant capacities of curcumin and  
(2E,6E)-2,6-Bis(3,5-dimethoxybenzylidene)cyclohexanone 235 (MCH, Figure 24) [164]. The 
compound is relatively stable by comparison to curcumin and shows enhanced anti-oxidative 
performance in vitro. Rat pheochromocytoma PC12 cells, a model for neurological cells under Aβ 
oxidative stress, were found to be protected from H2O2 injury by maintaining endogenous antioxidant 
enzyme activity, scavenging for reactive oxygen species and shielding cells from H2O2-induced 
cytotoxicity and apoptosis. In vivo experiments for MCH were not conducted, but the in vitro results 
suggest a promising avenue for further exploration. 
 
Figure 24. A potential Aβ peptide blocker (235) and an in vitro chloroquine-sensitive  
(CQ-S) and chloroquine-resistant (CQ-R) P. falciparum MAC antimalarial (236). 




Malaria is a serious infectious disease characterized by fevers, chills and flu-like illness. It is 
transmitted by Anopheles mosquitos infected with five known species of Plasmodium parasites, which 
include P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Three of the five species have 
been reported to exhibit drug-resistant behavior, while Plasmodium parasites are gaining resistance against 
an increasing number of different anti-malarial drugs. With the growing issue of drug-resistance, it is 
of paramount interest to search for alternative anti-malarial drugs that are effective and inexpensive. 
Several studies indicate that curcumin and its analogs may well serve as effective anti-malarial 
agents. According to Reddy and co-workers, curcumin delivers significant anti-malarial activity both 
in vitro and in vivo [165]. Curcumin inhibits chloroquine-resistant Plasmodium falciparum in culture 
in a dose-dependent manner (IC50 5 μM). In the in vivo experiments, curcumin was orally administered 
to P. berghei-infected mice in a dose known to be safe for humans. The drug treatment resulted in an 
80%–90% reduction in blood parasitemia, and curcumin treated mice experienced an overall survival 
rate of 29% compared to 0% for the non-treated control. In another study by Mishra and colleagues,  
in vitro experiments were performed to examine the effectiveness of curcumin and its analogs against 
red blood cell cultures containing either chloroquine-sensitive (CQ-S) or chloroquine-resistant (CQ-R) 
P. falciparum [166]. The agent was found to significantly inhibit the growth of both CQ-S (IC50 7.9 
μM) and CQ-R (IC50 29.6 μM) in red blood cell cultures. Several structural modifications of curcumin 
were also tested against both CQ-S and CQ-R, and many exhibited enhanced inhibitory activity. A 
pyrazole analog 236 (Figure 24) demonstrated the most effective inhibitory performance among the 
compounds tested (CQ-S (IC50 0.48 μM) and CQ-R (IC50 3.9 μM)). The authors speculated that the 
improved anti-malarial activity of 226 arises from increased cellular uptake and retention as well as 
greater inhibitory potency against the target itself. 
A more recent study evaluated the antimalarial activity of MACs against the two strains of  
P. falciparum, and found that the compounds exhibit significant anti-malarial behavior in an in vitro 
setting [167]. Twenty different MACs were tested against P. falciparum cultures and six of them were 
found to provide excellent inhibition of both CQ-R and CQ-S (237, 238, IC50 < 1 μM, Figure 25). 
Considering the increased bioavailability and stability of MACs as well as their enhanced anti-malarial 
abilities, this class of molecules offers an intriguing direction for further molecular design opportunities. 
237 238 
Figure 25. Potent in vitro CQ-R and CQ-S inhibitors of the P. falciparum parasite (237–238). 
9. Summary 
A host of MACs has shown potent anti-tumorigenic activity when tested by in vitro and in vivo 
models spanning a wide range of cancers and inflammatory conditions. Although a number of 
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structure-activity relationship (SAR) studies reveal useful correlations within a limited structural set of 
analogs [168], a truly broad analysis has yet to be achieved. Likewise, few of the reported structure 
activity studies make an attempt to deal with the subtle impact of 3D geometry as implied by Figure 4. 
To be sure, the size and electronegativity of substituents on the terminal aromatic rings (Figure 10) and 
the rigidity of the spacers between these rings may influence the in vitro biological actions of MAC’s. 
In addition, four other features have surfaced as advantageous elements for overall improved activity: 
(1) A doubly conjugated carbonyl is generally more potent than a single enone; (2) Double or triple 
methoxy substitution on the terminal aromatic rings, often accompanied by an aromatic OH group, 
frequently provides increased activity; (3) Terminal pyridine rings furnish both superior potency and 
solubility; (4) A piperidone ring at the center of a MAC not only imparts solubility, but also creates the 
opportunity to append extensions through an amide-like linker with additional beneficial properties. 
Assuming protein binding sites can tolerate such structural modification, specific and selective targeting 
might be an option. One example illustrated by in vivo testing involved the coupling of EF24 (6) to 
coagulation factor VIIa followed by protein-protein interaction with tissue factor leading to endocytosis 
and targeted delivery of the drug to the cytoplasm of MDA-MB-231 breast cancer cells. To date, this 
has not yet blossomed into a predictive and fruitful pathway for investigation, most likely because 
there are no X-ray structures of the corresponding ligand-protein complexes at present. It goes without 
saying that the same situation exists for the parent template with no single macromolecule-curcumin 
solid-state structure having been solved. In spite of the paucity of well-determined MAC-protein 
structural models, a growing number of investigations highlight that MACs are superior to curcumin  
in vitro by a 10–20 fold potency gain across a wide range of cancer cell lines, inflammation models 
and against numerous signaling proteins and transcription factors. Likewise, murine-based in vivo 
studies demonstrate clearly that MACs with appropriate pharmacokinetic and ADME properties 
(Absorption, Distribution, Metabolism and Excretion) can be conceived, prepared and tested for 
potential relief of human cancer, inflammatory diseases and other conditions. Similarly, by virtue of 
their improved physical properties, MACs have successfully demonstrated good PK profiles in mice 
and promoted tumor regression in cancer xenografts as well as orthotopic models in vivo; almost 
always more efficacious by comparison to curcumin. Though the literature is not yet deep, chemical 
and biological efforts to create MACs with the potential to relieve TB, Alzheimer’s, malaria and other 
maladies is underway. Based on the available data, it would appear that many of the underlying 
biochemical mechanisms controlling the latter conditions are common. One can be hopeful and 
optimistic that new developmental drugs might be capable of cross-treating any number of them. 
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